Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

2015799 citationsJournal Articlebronze Open Access

Authors

Michael P. Curry · Hadassah Medical Center

Jacqueline G. O’Leary · Baylor University Medical Center

Natalie Bzowej · Ochsner Medical Center

Andrew J. Muir · Duke University

Kevin Korenblat · Washington University in St. Louis

Jonathan M. Fenkel · Thomas Jefferson University

K. Rajender Reddy

Abstract

Treatment with sofosbuvir-velpatasvir with or without ribavirin for 12 weeks and with sofosbuvir-velpatasvir for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infection and decompensated cirrhosis. (Funded by Gilead Sciences; ASTRAL-4 ClinicalTrials.gov number, NCT02201901.).

Topics & Keywords

Hepatitis C virus research Liver Disease Diagnosis and Treatment Hepatitis B Virus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 27, pp. 2618-2628

DOI: 10.1056/nejmoa1512614

Field-Weighted Citation Impact: 61.35